Early stage life sciences company iBIONICS has had “a phenomenal year of growth and learning,” says CEO and co-founder Suzanne Grant.
The company, which is developing a bionic-eye system to restore vision in people with retinal degenerative diseases, has reached combined private and public funding goals of US$2.5 million and added another $1.5 million in grants; it also expects to finalize additional pre-seed financing in the next two quarters.
The firm has secured an exclusive worldwide licence for its prototype and has recently celebrated several other business and technical milestones.
Should artificial intelligence help you make your biggest and riskiest financial transaction? Real estate lawyer Matt Mayo has some advice.
Ms. Grant and iBIONICS were also chosen to exhibit at the Accessibility Innovation Showcase at the Invictus Games in Toronto in September.